Varex Imaging (VREX) Q2 2026

Q2 2026 Q1 2026 Q4 2025 Q3 2025

Earnings

Varex Imaging delivered a mixed second quarter for fiscal 2026, matching the Wall Street consensus on earnings while falling just short on the top line, as margin pressure and one-time costs clouded an otherwise steady operational picture. The medica… Read more Varex Imaging delivered a mixed second quarter for fiscal 2026, matching the Wall Street consensus on earnings while falling just short on the top line, as margin pressure and one-time costs clouded an otherwise steady operational picture. The medical imaging component maker posted non-GAAP EPS of $0.21, in line with the $0.21 consensus estimate, on revenue of $216.00 million, up 1.5% year over year but fractionally below the $216.92 million analysts had expected. The more striking headline, however, was a GAAP net loss of $8.10 million, driven largely by $9.40 million in debt-extinguishment costs tied to a March refinancing and $3.80 million in non-ordinary litigation expenses; adjusted EBITDA fell to $26.60 million from $36.20 million a year earlier, reflecting both the margin compression and elevated operating costs. Medical segment revenue edged up to $156.20 million, though gross profit there declined, while the Industrial segment held firm at $59.80 million with improved profitability. Management reinstated full-year guidance, targeting revenue of $860 million to $880 million and non-GAAP EPS of $0.80 to $1.00, with second-half revenue expected to grow roughly 3% versus the prior year, though tariff headwinds remain an acknowledged risk embedded in that outlook.